Subcommittee Hearing Biosimilar Implementation: A Progress Report from FDA
DirectorCenter for Drug Evaluation and Research, Food and Drug AdministrationSilver Spring, MD
- Adobe Acrobat DocumentDownload Testimony
Those in need of accommodations, including closed captioning for webcast hearings, should contact the Committee at 202-224-5375 or email@example.com. So as to best enable staff to make arrangements, please call or email at least 3 business days in advance of the hearing.